SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

Read more breaking news

 

 

inVentiv preps for $100m IPO

By Gareth MacDonald+

06-Apr-2016
Last updated on 06-Apr-2016 at 17:03 GMT2016-04-06T17:03:15Z

inVentiv preps for $100m IPO

US CRO inVentiv Health has signaled its intention to go public by filing an S1 with the Securities and Exchange Commission (SEC) last night.

According to the S1 , which was filed by parent company inVentiv Group Holding, the Burlington, Massachusetts-based contract services organisation hopes to raise $100m by listing on either the New York Stock Exchange or the NASDAQ Global Market.

inVentiv has been owned by US private equity group Thomas H Lee Partners (THL), which acquired the contractor in 2010 for $1.1bn (€845m).

According to the S1, inVentiv generated net revenues of $1.99bn last year, which is an increase of 10.4% year-on-year.

The document also reveals that the firm's clinical trial business generated revenue of $947m, up 8.9%, while its commercial services unit – which helps drug firms launch products – saw sales of $1bn, which is up 12.3% from 2014.

inVentiv claims to have a client base of more than 550 organizations, including the 20 of the largest global biopharmaceutical companies.

It also says that over 80% of all new molecular entities approved by the US FDA and 70% of those approved by the EMA over the last five years "have been developed or commercialized with our support."

Related products

Related suppliers

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...